Pet pharmaceutical company Putney, which is focused on the development and sale of generic prescription medicines for pets, has sold 100% of the company to Dechra Holdings US, a subsidiary of Dechra Pharmaceuticals for $200 million. Dechra Pharmaceuticals is a UK-based company that develops, manufactures and sells specialty veterinary pharmaceuticals and related products, reported FY2015 revenues of £203.5million ($300 million). Putney’s net revenues were $49.6 million in 2015. Upon clo...